Protocol Ledger

NCT07491458 · Phase II · RECRUITING

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

Interventional Phase II clinical trial protocol NCT07491458 sponsored by Rivus Pharmaceuticals in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-02-13 Enrollment: 180 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07491458
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)180 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)0 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07491458
Protocol FieldVerified Registry Value
NCT IdentifierNCT07491458
Consolidated Lead SponsorRivus Pharmaceuticals
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment180 participants (ESTIMATED)
Registered Start Date2026-02-13
WhyStopped ClassificationNot Stopped

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI